To investigate the anti-tumor efficacy of targeting EZH2 in TCL, we conducted a cell viability assay on tumor cell lines treated with the EZH1/2 inhibitor Valemetostat, the EZH2 PROTAC degrader MS177, the EZH2 inhibitor EPZ6438 and SHR2554 (Supplementary Fig. S3A). This evidence concerns the gene EZH2 and neoplasm.